Thorstein Saeter1,2, Ljiljana Vlatkovic3, Gudmund Waaler2, Einar Servoll2, Jahn M Nesland1,3, Karol Axcrona4, Ulrika Axcrona3. 1. Medical Faculty, University of Oslo, Oslo, Norway. 2. Department of Surgery, Sørlandet Hospital Arendal, Arendal, Norway. 3. Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 4. Department of Urology, Akershus University Hospital, Lørenskog, Norway.
Abstract
BACKGROUND: Previous studies suggest that lymphovascular invasion (LVI) has a weak and variable effect on prognosis. It is uncertain whether LVI, determined by diagnostic prostate biopsy, predicts prostate cancer death. Data from experimental studies have indicated that carcinoma-associated fibroblasts in the reactive stroma could promote LVI and progression to metastasis. Thus, combining LVI with reactive stromal grade may identify prostate cancer patients at high risk of an unfavorable outcome. The purpose of the present study was to examine if LVI, determined by diagnostic biopsy, alone and in combination with reactive stromal grade could predict prostate cancer death. METHODS: This population-based study included 283 patients with prostate cancer diagnosed by needle biopsy in Aust-Agder County (Norway) from 1991 to 1999. Clinical data were obtained by medical charts review. Two uropathologists evaluated LVI and reactive stromal grade. The endpoint was prostate cancer death. RESULTS: Patients with LVI had marginally higher risk of prostate cancer death compared to patients without LVI (hazard ratio: 1.8, P-value = 0.04). LVI had a stronger effect on prostate cancer death risk when a high reactive stromal grade was present (hazard ratio: 16.0, P-value <0.001). Therefore, patients with concomitant LVI and high reactive stromal grade were at particularly high risk for prostate cancer death. CONCLUSIONS: Evaluating LVI together with reactive stromal grade on diagnostic biopsies could be used to identify patients at high risk of death from prostate cancer. Prostate 76:1088-1094, 2016.
BACKGROUND: Previous studies suggest that lymphovascular invasion (LVI) has a weak and variable effect on prognosis. It is uncertain whether LVI, determined by diagnostic prostate biopsy, predicts prostate cancer death. Data from experimental studies have indicated that carcinoma-associated fibroblasts in the reactive stroma could promote LVI and progression to metastasis. Thus, combining LVI with reactive stromal grade may identify prostate cancerpatients at high risk of an unfavorable outcome. The purpose of the present study was to examine if LVI, determined by diagnostic biopsy, alone and in combination with reactive stromal grade could predict prostate cancer death. METHODS: This population-based study included 283 patients with prostate cancer diagnosed by needle biopsy in Aust-Agder County (Norway) from 1991 to 1999. Clinical data were obtained by medical charts review. Two uropathologists evaluated LVI and reactive stromal grade. The endpoint was prostate cancer death. RESULTS:Patients with LVI had marginally higher risk of prostate cancer death compared to patients without LVI (hazard ratio: 1.8, P-value = 0.04). LVI had a stronger effect on prostate cancer death risk when a high reactive stromal grade was present (hazard ratio: 16.0, P-value <0.001). Therefore, patients with concomitant LVI and high reactive stromal grade were at particularly high risk for prostate cancer death. CONCLUSIONS: Evaluating LVI together with reactive stromal grade on diagnostic biopsies could be used to identify patients at high risk of death from prostate cancer. Prostate 76:1088-1094, 2016.
Authors: Michelle R Downes; John R Srigley; Andrew Loblaw; Nathan Perlis; Sangeet Ghai; Theodorus van der Kwast Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 1.862
Authors: William Gesztes; Cara Schafer; Denise Young; Jesse Fox; Jiji Jiang; Yongmei Chen; Huai-Ching Kuo; Kuwong B Mwamukonda; Albert Dobi; Allen P Burke; Judd W Moul; David G McLeod; Inger L Rosner; Gyorgy Petrovics; Shyh-Han Tan; Jennifer Cullen; Shiv Srivastava; Isabell A Sesterhenn Journal: Sci Rep Date: 2022-03-30 Impact factor: 4.996